FDA hits Apotex with second warning on GMP violations
This article was originally published in Scrip
Executive Summary
The US FDA has hit Apotex with another warning letter for good manufacturing practice violations, this time citing a Toronto facility for allowing contaminated material to be reprocessed and repackaged into finished drug products that were shipped to the US.